WallStreetZenWallStreetZen

NASDAQ: ADXN
Addex Therapeutics Ltd Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their ADXN stock forecasts and price targets.

Forecast return on equity

Is ADXN forecast to generate an efficient return?

Forecast return on assets

Is ADXN forecast to generate an efficient return on assets?
Company
-40,378.08%
Industry
4.88%
ADXN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ADXN earnings per share forecast

What is ADXN's earnings per share in the next 1 years based on estimates from 1 analyst?
Avg 1 year Forecast
-$11.80

ADXN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ADXN$8.26N/AN/A
ABVC$0.79N/AN/A
ONVO$0.62N/AN/A
KA$0.73$8.00+995.89%Buy
CYCN$2.95N/AN/A

Addex Therapeutics Stock Forecast FAQ

What is ADXN's earnings growth forecast for 2024-2024?

(NASDAQ: ADXN) Addex Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of N/A, and while it is not forecast to beat the US market's average forecast earnings growth rate of N/A.

Addex Therapeutics's earnings in 2024 is -$12,624,940.

In 2024, ADXN is forecast to generate -$1,513,539,473 in earnings, with the lowest earnings forecast at -$1,513,539,473 and the highest earnings forecast at -$1,513,539,473.

If you're new to stock investing, here's how to buy Addex Therapeutics stock.

What is ADXN's forecast return on equity (ROE) for 2024-2024?

(NASDAQ: ADXN) forecast ROE is N/A, which is considered weak.

What is ADXN's Earnings Per Share (EPS) forecast for 2024-2024?

(NASDAQ: ADXN) Addex Therapeutics's current Earnings Per Share (EPS) is -$0.15. In 2024, ADXN's EPS is forecast to hit -$11.80 (min: -$11.80, max: -$11.80).

What is ADXN's forecast return on assets (ROA) for 2024-2024?

(NASDAQ: ADXN) forecast ROA is -40,378.08%, which is lower than the forecast US Biotechnology industry average of 4.88%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.